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Discussion
Dr Nasser K. Altorki (New York, NY). Dr Litle, I congratulate you
on a nice piece of work and nice presentation; I also congratulate
your group on bringing this new field of microRNA expression pro-
files into the field of esophageal and other thoracic malignancies,
particularly as related to using them as diagnostic tools, prognostic
tools, and, most importantly I think, as tools for target discovery and
mechanistically understanding better the biology. I think you have
shown very nicely here that microRNA expression profiles can re-
ally distinguish histologies, AC versus SCC, and I think that you
have also shown that the expression profiles can distinguish tumor
from NSE.
From a mechanistic point of view, I do not know if you have had
the opportunity to ascertain what the genomic sequence is that these
microRNAs would target, or maybe even look at the putative signal-
ing pathways that may be affected, for example, by mir-21, which,
as I understand, is overexpressed in a variety of malignancies, both
thoracic and extrathoracic, and has been found in at least one situa-
tion to target the p10 gene and its signaling pathway. I know you’ve
had some frozen tissue. I don’t know whether you were able to go
back and examine those samples, or whether that lies in your future
plans. That would be one question, the signaling pathways or the
target sequences on the genome.
The other curiosity really relates to the 5 patients who had BE
that appeared to have clustered either with squamous or AC or
NSE, as I recall. Do you have any further follow-up with those pa-
tients to see whether those molecular signatures really translated into
clinically significant outcomes?
Dr Litle. Thank you, Dr Altorki. With regard to the first ques-
tion, our lab is primarily focused currently on biomarkers and detec-
tion of occult disease. We aren’t involved in signal transduction
research at this time, but certainly those are important questions.
This is a relatively new field, and a lot is still not known about micro-
RNAs in general. They are involved in cell differentiation, apopto-
sis, and proliferation, which emphasizes how little we know. Your
questions will need to be answered with future studies.
Regarding the 5 patients with BE, we don’t have any follow-up.
The next step will be to validate the results with expression data. We
have a bank of paraffin-embedded samples of dysplasia, BE speci-
mens, and more AC specimens to add to our small sample here.
We would use the microRNA expression profiles on a larger series
and then design appropriate primers for reverse transcriptase–poly-
merase chain reaction so we could complete quantitative reverse
transcriptase–polymerase chain reaction for patients with follow-
up. Ideally, we would do follow-up on patients with BE—some
with cancer and some not—so we could correlate the results. These
research questions will be addressed in a newly funded National
Institutes of Health grant.
Dr Thomas A. D’Amico (Durham, NC). How much tissue do
you need to do the microRNA testing, and can you envisage a tech-
nique that wouldn’t require endoscopy to get the same information?
Dr Litle.Youmean to get the same information as far as whether
someone has BE?
Dr D’Amico. Right. The goal is to take patients with BE or even
just reflux and determine which ones are going to have BE or cancer.
Can you envisage a way to do that without endoscopy?
DrLitle.Use of serummarkers for identifyingBE in patientswith
reflux and cancer in patients with BE unfortunately doesn’t appear to
be available in the near future. We’re not even at the point of being
able to do this efficiently by endoscopic biopsy; we currently need
enough tissue for both histologic and RNA analyses. Adequate endo-
scopic biopsy samples for molecular analysis of patients with BE
would be our goal in the near future should our hypotheses prove true.
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